Cantor analyst William Tanner is out pounding the table on shares of TherapeuticsMD (NASDAQ:TXMD), reiterating an Overweight rating and price target of $26, which implies an upside of 334% from current levels.
Tanner wrote, “We maintain our viewpoint that Imvexxy will become an important treatment for symptoms of vulvar vaginal atrophy (VVA) and that the product’s commercial performance will be the key determinant of TXMD stock performance over the next 12-18 months. We believe TX-001 possesses the clear advantage, vs. compounded estrogen plus progesterone (E+P), of potentially being the only FDA-approval E +P product, but suspect investors will view the Imvexxy roll out as a barometer of management’s general commercialization capabilities.”
“TX-001’s PDUFA date is October 28 and we believe the likelihood of FDA approval is high. Management noted that novel data from clinical testing that speak to effects on weight gain, blood pressure and other metabolic parameters will be presented at NAMS (San Diego, October 3-6). With an FDA decision likely not rendered before then, TXMD will be limited (perhaps forbidden) in what can be said about the drug candidate, but we believe general disease awareness commentary could help position the story,” the analyst continued.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst William Tanner has a yearly average return of 1.7% and a 47% success rate. Tanner has a 9.4% average return when recommending TXMD, and is ranked #2246 out of 4836 analysts.
Over the last 12 months, TherapeuticsMD stock has received a whopping 9 Buy ratings and just 1 Hold ratings. As a result, the stock has a ‘Strong Buy’ analyst consensus rating. These analysts believe (on average) that the drug maker has big upside potential of nearly 130% from the current share price. This would take TMXD from $55.29 all the way to $13.78.
TherapeuticsMD is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.